Literature DB >> 26093076

Twenty-two years of candidaemia surveillance: results from a Norwegian national study.

L Hesstvedt1, P Gaustad2, C T Andersen3, E Haarr4, R Hannula5, H H Haukland6, N-O Hermansen7, K W Larssen8, H Mylvaganam9, T E Ranheim10, P Sandven11, I Nordøy12, A Kanestrøm, C Grub, A Onken, C Thielsen, D Skaare, S Tofteland, L-J Sønsteby, R Hjetland, R Hide, E Vik, A Kümmel, S Åsheim.   

Abstract

Several studies have reported an increased incidence of candidaemia and a redistribution of species, with a decrease in the number of Candida albicans isolates. In Norway, a prospective, national surveillance study of candidaemia has been ongoing since 1991. Data from the period 1991-2003 have been published previously. The aim of this study was to follow up the incidence, species distribution and antifungal susceptibility of Candida species isolates from blood cultures in the period 2004-2012, and compare them with the corresponding findings from the period 1991-2003. Blood culture isolates of Candida species from all medical microbiological laboratories in Norway were identified and susceptibility tested at the Norwegian Mycological Reference Laboratory. A total of 1724 isolates were recovered from 1653 patients in the period 2004-2012. Comparison of the two periods showed that the average incidence of candidaemia episodes per 100 000 inhabitants increased from 2.4 (1991-2003) to 3.9 (2004-2012). The increase in incidence in the latter period was significantly higher in patients aged >40 years (p 0.001), and a marked increase was observed in patients aged >60 years (p < 0.001). In conclusion, the average incidence in Norway over a period of 22 years modestly increased from 2.4 to 3.9 per 100,000 inhabitants, this being mainly accounted for by candidaemia in the elderly. The species distribution was stable, and the rate of acquired resistance was low.
Copyright © 2015 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Antifungal susceptibility; candidaemia; population-based incidence; species distribution; surveillance

Mesh:

Substances:

Year:  2015        PMID: 26093076     DOI: 10.1016/j.cmi.2015.06.008

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  35 in total

1.  Change in species distribution and antifungal susceptibility of candidemias in an intensive care unit of a university hospital (10-year experience).

Authors:  Bilgul Mete; Esra Yerlikaya Zerdali; Gokhan Aygun; Nese Saltoglu; Ilker Inanc Balkan; Ridvan Karaali; Sibel Yildiz Kaya; Berna Karaismailoglu; Abdurrahman Kaya; Seval Urkmez; Gunay Can; Fehmi Tabak; Recep Ozturk
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2020-09-15       Impact factor: 3.267

2.  Epidemiology and reporting of candidaemia in Belgium: a multi-centre study.

Authors:  C Trouvé; S Blot; M-P Hayette; S Jonckheere; S Patteet; H Rodriguez-Villalobos; F Symoens; E Van Wijngaerden; K Lagrou
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-11-17       Impact factor: 3.267

Review 3.  Antifungal Susceptibility Testing: Current Approaches.

Authors:  Elizabeth L Berkow; Shawn R Lockhart; Luis Ostrosky-Zeichner
Journal:  Clin Microbiol Rev       Date:  2020-04-29       Impact factor: 26.132

Review 4.  Molecular and genetic basis of azole antifungal resistance in the opportunistic pathogenic fungus Candida albicans.

Authors:  Andrew T Nishimoto; Cheshta Sharma; P David Rogers
Journal:  J Antimicrob Chemother       Date:  2020-02-01       Impact factor: 5.790

Review 5.  Candida parapsilosis: from Genes to the Bedside.

Authors:  Renáta Tóth; Jozef Nosek; Héctor M Mora-Montes; Toni Gabaldon; Joseph M Bliss; Joshua D Nosanchuk; Siobhán A Turner; Geraldine Butler; Csaba Vágvölgyi; Attila Gácser
Journal:  Clin Microbiol Rev       Date:  2019-02-27       Impact factor: 26.132

6.  Posttreatment Antifungal Resistance among Colonizing Candida Isolates in Candidemia Patients: Results from a Systematic Multicenter Study.

Authors:  R H Jensen; H K Johansen; L M Søes; L E Lemming; F S Rosenvinge; L Nielsen; B Olesen; L Kristensen; E Dzajic; K M T Astvad; M C Arendrup
Journal:  Antimicrob Agents Chemother       Date:  2015-12-28       Impact factor: 5.191

7.  Update from a 12-Year Nationwide Fungemia Surveillance: Increasing Intrinsic and Acquired Resistance Causes Concern.

Authors:  K M T Astvad; H K Johansen; B L Røder; F S Rosenvinge; J D Knudsen; L Lemming; H C Schønheyder; R K Hare; L Kristensen; L Nielsen; J B Gertsen; E Dzajic; M Pedersen; C Østergård; B Olesen; T S Søndergaard; M C Arendrup
Journal:  J Clin Microbiol       Date:  2018-03-26       Impact factor: 5.948

8.  Propensity Score Analysis of the Role of Initial Antifungal Therapy in the Outcome of Candida glabrata Bloodstream Infections.

Authors:  M Puig-Asensio; M Fernández-Ruiz; J M Aguado; P Merino; D Lora-Pablos; J Guinea; P Martín-Dávila; M Cuenca-Estrella; B Almirante
Journal:  Antimicrob Agents Chemother       Date:  2016-05-23       Impact factor: 5.191

9.  Antifungal Susceptibility of Clinical Yeast Isolates from a Large Canadian Reference Laboratory and Application of Whole-Genome Sequence Analysis To Elucidate Mechanisms of Acquired Resistance.

Authors:  Lisa R McTaggart; Ana Cabrera; Kirby Cronin; Julianne V Kus
Journal:  Antimicrob Agents Chemother       Date:  2020-08-20       Impact factor: 5.191

10.  Invasive Candidiasis Species Distribution and Trends, United States, 2009-2017.

Authors:  Emily E Ricotta; Yi Ling Lai; Ahmed Babiker; Jeffrey R Strich; Sameer S Kadri; Michail S Lionakis; D Rebecca Prevots; Jennifer Adjemian
Journal:  J Infect Dis       Date:  2021-04-08       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.